康艾注射液联合化疗治疗晚期非小细胞肺癌疗效的Meta分析  

The Meta Analysis of Efficacy of Kangai Injection Combined with Chemotherapy for Advanced Nonsmall Cell Lung Cancer

作　　者：周翔辉[1] 闫志国[1] 刘文攀 倪昌国 肖桂华 徐忠能[1] ZHOU Xianghui;YAN Zhiguo;LIU Wenpan;NI Changguo;XIAO Guihua;XU Zhongneng(The First People’s Hospital of Kunming,Kunming 650011,China;不详)

机构地区：[1]昆明市第一人民医院,云南昆明650011

出　　处：《中国医学创新》2021年第4期111-117,共7页Medical Innovation of China

摘　　要：目的:评价康艾注射液联合化疗治疗晚期非小细胞肺癌(NSCLC)的疗效。方法:计算机检索中国知网(CNKI)、万方数据库、维普数据库(VIP)、中国生物医学文献数据库(CBM)、PubMed、Embase、Cochrane library等中英文数据库近10年有关康艾注射液联合化疗治疗晚期NSCLC的随机对照试验。文献质量进行评价后对符合标准的文献予以纳入,提取研究结果等相应指标,用RevMan5.0软件对治疗总有效率、治疗后KPS评分、骨髓抑制发生情况、胃肠道反应发生率等指标进行Meta分析。结果:共纳入16篇文献,1223例患者纳入研究,康艾注射液联合化疗组在总有效率[RR=1.44,95%CI(1.26,1.65),P<0.01]、KPS评分改善情况[RR=0.56,95%CI(0.02,1.09),P<0.01]和减轻胃肠道反应[RR=0.62,95%CI(0.53,0.72),P<0.01]方面优于单纯化疗组;在减轻骨髓抑制方面的亚组分析显示,对于减轻Ⅰ°~Ⅱ°骨髓抑制,联合组和单纯化疗组效果相当,差异无统计学意义[RR=0.83,95%CI(0.69,1.00),P=0.05],但在减轻Ⅲ°~Ⅳ°骨髓抑制上,联合组明显优于单纯化疗组[RR=0.40,95%CI(0.26,0.62),P<0.01],并且最终亚组合并效应为联合组优于单纯化疗组[RR=0.70,95%CI(0.59,0.83),P<0.01]。结论:康艾注射液联合化疗治疗晚期NSCLC有一定增效、减毒、减轻不良反应的作用,但由于所纳入文献质量均为小样本、单中心研究,可能存在一定偏倚,尚需更多多中心随机对照试验进一步证实。Objective:To evaluate the efficacy of Kangai injection combined with chemotherapy for advanced non-small cell lung cancer(NSCLC).Method:The databases like CNKI,Wangfang,VIP,CBM,PubMed,Embase and Cochrane library for RCT about the treatment of Kangai Injection combined with chemotherapy for advanced NSCLC were searched.After the evaluation of the quality of the literatures,the literatures meeting the standards were included,and the corresponding indicators such as the research results were extracted.The total effective rate,KPS score after treatment,incidence of myelosuppression,incidence of gastrointestinal reactions and other indicators were meta analyzed by revman5.0 software.Result:16 studies and 1223 patients were absorbed into this article.Kangai Injection combined chemotherapy group in the total effective rate[RR=1.44,95%CI(1.26,1.65),P<0.01],KPS improvement[RR=0.56,95%CI(0.02,1.09),P<0.01]and reducing the gastrointestinal reaction[RR=0.62,95%CI(0.53,0.72),P<0.01]was better than pure chemotherapy group.The subgroup analysis of reducing the bone marrow suppression showed:for reducing theⅠ°-Ⅱ°bone marrow suppression,there was no statistically significant difference in these two groups[RR=0.83,95%CI(0.69,1.00),P=0.05];but in reducing theⅢ°-Ⅳ°marrow suppression,Kangai Injection combined chemotherapy group is better than pure chemotherapy group[RR=0.40,95%CI(0.26,0.62),P<0.01],in total effect,the experimental group was better than the control group[RR=0.70,95%CI(0.59,0.83),P<0.01].Conclusion:Kangai Injection combined chemotherapy for advanced NSCLC can increase curative effect and reduce the toxicity of chemotherapy,however quality are included in the literature are based on small samples,single-center study,we meed more polycentric study to prove further.

关 键 词：康艾注射液 化疗 晚期非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]